



LTZ Therapeutics Forms Strategic Partnership with the Institute for Follicular Lymphoma Innovation (IFLI) to Advance Phase 1 Novel Bispecific Myeloid Engager Antibody for B-Cell Malignancies

IFLI backs LTZ-301, a novel bispecific antibody targeting CD79b and proprietary myeloid receptor for follicular lymphoma and other blood cancers

The Institute for Follicular Lymphoma Innovation (IFLI) is pleased to announce its investment in LTZ Therapeutics (LTZ), an immunotherapy-focused biotechnology company, and support LTZ's phase 1 clinical trial of myeloid engager LTZ-301 in patients with relapsed/refractory non Hodgkin lymphoma (NHL), including follicular lymphoma (FL).

LTZ-301 is a bispecific antibody engineered to target CD79b—a protein predominantly expressed in B-cell malignancies—and a proprietary myeloid receptor. By selectively binding to CD79b, which persists following relapse and is primarily confined to B-cells, and recruiting myeloid cells to the tumor microenvironment, LTZ-301 has promise to enhance each patient's anti-cancer immune response and reduce off-target effects while improving patient outcomes.

IFLI joined LTZ, bringing funding in round of funding and facilitating the expanding inclusion of additional follicular lymphoma patients in LTZ's phase 1 clinical trial.

IFLI congratulates LTZ on inking its research partnership with Eli Lilly, announced on July 29, to develop novel myeloid engager therapeutics for diseases with significant unmet needs. LTZ will receive an upfront payment in the double-digit millions (USD) and an equity investment, with the agreement covering various development, regulatory, and commercialization milestones.

"IFLI's partnership with LTZ marks a pivotal milestone in the clinical advancement of a next-generation immunotherapy uniquely designed to harness myeloid cell engagement and selectively target CD79b. This collaboration underscores our shared commitment to transforming the therapeutic landscape for patients with hematologic malignancies" said Michel Azoulay, Chief Medical Officer of IFLI.

###

About LTZ Therapeutics:

LTZ Therapeutics is an immunotherapy-focused biotechnology company pursuing the development of novel therapies, with the company's novel Myeloid Engager Platform, to improve clinical outcomes in patients with cancer and autoimmune diseases. With main operations in Redwood City, California and Shenzhen China as well as a team out of Heidelberg Germany, LTZ is dedicated to developing myeloid engager immunotherapies for broad disease indications. For more information, please visit <https://www.ltztherapeutics.com/>.

About IFLI

The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at www.i-fl.org.